- The Quantiferon-TB Gold Plus blood test is designed to detect latent tuberculosis in patients.
- Teva Pharmaceuticals gained approval for the first generic version of Gilead Science’s best-selling HIV drug Truvada.
- Symjepi is a single-dose prefilled syringe of epinephrine intended to treat emergency allergic reactions, including anaphylaxis.
- Mydayis is intended to treat ADHD symptoms in patients thirteen years or older.
- Cotempla is an extended-release orally disintegrating tablet intended to treat ADHD in patients ages 6 to 17 years.
- Baxdela is intended to treat skin and skin structure infections caused by various gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus.
- Haegarda is the first self-administered C1 esterase inhibitor subcutaneous injection to prevent swelling attacks in patients with hereditary angiodema.
More articles on supply chain:
Drug manufacturer, distributor shut down for producing unapproved medications
Sanofi CEO on SCOTUS’ biologics ruling: 3 takeaways
Whole Foods acquisition could move Amazon closer to pharmacies
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.